MAK16

Summary

MAK16 (MAK16 homolog, HGNC:13703) is a protein-coding gene on chromosome 8p12, encoding Protein MAK16 homolog (Q9BXY0). It is a common-essential gene (DepMap: required in 100.0% of cancer cell lines).

Enables RNA binding activity. Predicted to be involved in maturation of 5.8S rRNA and maturation of LSU-rRNA. Located in nucleolus.

Source: NCBI Gene 84549 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 66 total — 1 pathogenic
• Phenotypes (HPO): 1
• Cancer dependency (DepMap): dependent in 100.0% of screened cell lines (common-essential)
• MANE Select transcript: NM_032509

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13703
Approved symbol	MAK16
Name	MAK16 homolog
Location	8p12
Locus type	gene with protein product
Status	Approved
Aliases	MAK16L
Ensembl gene	ENSG00000198042
Ensembl biotype	protein_coding
Entrez	84549

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 protein_coding, 3 retained_intron, 1 nonsense_mediated_decay

ENST00000360128, ENST00000517567, ENST00000518389, ENST00000519089, ENST00000520763, ENST00000929667, ENST00000929668, ENST00000929669, ENST00000929670, ENST00000954019

RefSeq mRNA: 1 — MANE Select: NM_032509 NM_032509

CCDS: CCDS6089

Canonical transcript exons

ENST00000360128 — 10 exons

Exon	Start	End
ENSE00000911608	33488988	33489139
ENSE00000911609	33490285	33490339
ENSE00001421531	33498432	33501262
ENSE00002131726	33485182	33485221
ENSE00003515491	33488378	33488427
ENSE00003533633	33488520	33488629
ENSE00003593628	33495542	33495616
ENSE00003616880	33488734	33488798
ENSE00003631690	33496625	33496741
ENSE00003667045	33497232	33497297

Expression profiles

Bgee: expression breadth ubiquitous, 275 present calls, max score 90.15.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 25.5906 / max 633.0842, expressed in 1795 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
88392	24.2080	1794
88394	1.3826	781

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	90.15	gold quality
secondary oocyte	CL:0000655	89.88	gold quality
oocyte	CL:0000023	88.99	gold quality
tendon	UBERON:0000043	87.23	gold quality
tibialis anterior	UBERON:0001385	86.54	gold quality
deltoid	UBERON:0001476	86.05	silver quality
buccal mucosa cell	CL:0002336	85.70	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.55	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.43	gold quality
oviduct epithelium	UBERON:0004804	84.66	gold quality
cervix squamous epithelium	UBERON:0006922	84.54	silver quality
gluteal muscle	UBERON:0002000	84.34	gold quality
parietal pleura	UBERON:0002400	83.71	gold quality
biceps brachii	UBERON:0001507	83.67	gold quality
adrenal tissue	UBERON:0018303	83.60	gold quality
pleura	UBERON:0000977	83.28	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	83.00	silver quality
endometrium	UBERON:0001295	82.94	gold quality
islet of Langerhans	UBERON:0000006	82.71	gold quality
palpebral conjunctiva	UBERON:0001812	82.60	gold quality
cartilage tissue	UBERON:0002418	82.48	gold quality
stromal cell of endometrium	CL:0002255	82.28	gold quality
skeletal muscle tissue	UBERON:0001134	82.23	gold quality
gastrocnemius	UBERON:0001388	82.06	gold quality
muscle of leg	UBERON:0001383	82.02	gold quality
colonic epithelium	UBERON:0000397	82.01	gold quality
fallopian tube	UBERON:0003889	81.86	gold quality
visceral pleura	UBERON:0002401	81.74	gold quality
epithelium of mammary gland	UBERON:0003244	81.65	gold quality
mucosa of urinary bladder	UBERON:0001259	81.63	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.90

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

157 targeting MAK16, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 100.0% of screened cell lines, common-essential.

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	mak16	ENSDARG00000003527
mus_musculus	Mak16	ENSMUSG00000031578
rattus_norvegicus	Mak16	ENSRNOG00000010783
drosophila_melanogaster	Rbm13	FBGN0030067
caenorhabditis_elegans		WBGENE00015811

Protein

Protein identifiers

Protein MAK16 homolog — Q9BXY0 (reviewed: Q9BXY0)

Alternative names: NNP78, Protein RBM13

All UniProt accessions (2): Q9BXY0, H0YBV6

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Nucleus. Nucleolus.

Similarity. Belongs to the MAK16 family.

RefSeq proteins (1): NP_115898* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006958	Mak16	Family
IPR029004	Ribosomal_eL28/Mak16	Domain

Pfam: PF01778, PF04874

UniProt features (15 total): modified residue 5, compositionally biased region 3, cross-link 2, sequence conflict 2, chain 1, region of interest 1, sequence variant 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
8FKV	ELECTRON MICROSCOPY	2.47
8FKT	ELECTRON MICROSCOPY	2.81
8FKP	ELECTRON MICROSCOPY	2.85
8FKR	ELECTRON MICROSCOPY	2.89

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BXY0-F1	75.20	0.49

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 55, 151, 1, 197, 200, 229, 232

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 155 (showing top): GOBP_RIBOSOME_BIOGENESIS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, PUJANA_CHEK2_PCC_NETWORK, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, GOBP_MATURATION_OF_LSU_RRNA, GATA1_01, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP, chr8p12, GOBP_MATURATION_OF_5_8S_RRNA, SARTIPY_NORMAL_AT_INSULIN_RESISTANCE_UP, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, GOBP_RIBOSOMAL_LARGE_SUBUNIT_BIOGENESIS, BERENJENO_TRANSFORMED_BY_RHOA_UP, CAIRO_LIVER_DEVELOPMENT_UP, GOCC_PRERIBOSOME

GO Biological Process (2): maturation of 5.8S rRNA (GO:0000460), maturation of LSU-rRNA (GO:0000470)

GO Molecular Function (2): RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (3): nucleolus (GO:0005730), preribosome, large subunit precursor (GO:0030687), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
rRNA processing	2
ribosomal large subunit biogenesis	1
nucleic acid binding	1
binding	1
nuclear lumen	1
intracellular membraneless organelle	1
preribosome	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2305 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MAK16	WDR12	Q9GZL7	678
MAK16	NIFK	Q9BYG3	671
MAK16	RSL1D1	O76021	663
MAK16	PA2G4	Q9UQ80	627
MAK16	NIP7	Q9Y221	597
MAK16	PUS7	Q96PZ0	597
MAK16	GTPBP4	Q9BZE4	572
MAK16	POLR1B	Q9H9Y6	570
MAK16	PAK1IP1	Q9NWT1	558
MAK16	WDR74	Q6RFH5	523
MAK16	RRP36	Q96EU6	520
MAK16	EBNA1BP2	Q99848	517
MAK16	GNL3	Q9BVP2	515
MAK16	RSPH14	Q9UHP6	509
MAK16	RAB14	P35287	492

IntAct

107 interactions, top by confidence:

A	B	Type	Score
MAK16	FRMD6	psi-mi:“MI:0915”(physical association)	0.670
FRMD6	MAK16	psi-mi:“MI:0915”(physical association)	0.670
LIN28A	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
NPM1	NVL	psi-mi:“MI:0914”(association)	0.610
MAK16	LIN7B	psi-mi:“MI:0915”(physical association)	0.560
RPL28	MAGEB2	psi-mi:“MI:0914”(association)	0.560
HNRNPH2	PLOD2	psi-mi:“MI:0914”(association)	0.530
H1-4	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
ZNF2	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
MACROH2A2	PPM1G	psi-mi:“MI:0914”(association)	0.530
MAK16	NVL	psi-mi:“MI:0914”(association)	0.530
ZBTB48	ZBTB24	psi-mi:“MI:0914”(association)	0.530
RPF1	ZNF324	psi-mi:“MI:0914”(association)	0.530
MAGEB2	POLRMT	psi-mi:“MI:0914”(association)	0.530
H1-4	RRP8	psi-mi:“MI:0914”(association)	0.530
KRR1	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
NHSL3	NCK2	psi-mi:“MI:0914”(association)	0.530
ZNF71	DKC1	psi-mi:“MI:0914”(association)	0.530
MAK16	CSNK2A1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
CSNK2A2	WDR46	psi-mi:“MI:0914”(association)	0.350
SMC6	IFT88	psi-mi:“MI:0914”(association)	0.350
TSNAX		psi-mi:“MI:0914”(association)	0.350
Cep85l	CLK2	psi-mi:“MI:0914”(association)	0.350
PDGFRA	RNPS1	psi-mi:“MI:0914”(association)	0.350

BioGRID (231): MAK16 (Affinity Capture-MS), BRIX1 (Co-fractionation), MAK16 (Co-fractionation), MAK16 (Affinity Capture-MS), MAK16 (Affinity Capture-MS), MAK16 (Affinity Capture-MS), MAK16 (Affinity Capture-MS), MAK16 (Affinity Capture-MS), MAK16 (Affinity Capture-MS), MAK16 (Affinity Capture-MS), MAK16 (Affinity Capture-MS), MAK16 (Affinity Capture-MS), FRMD6 (Affinity Capture-MS), WDR74 (Affinity Capture-MS), TUBA8 (Affinity Capture-MS)

ESM2 similar proteins: A1CQN6, A3GGT2, A3GGV1, A5DNZ1, A5E203, A7A241, A7TJT3, A7TSJ7, A8P353, B4PKZ7, C5E1C7, F5HI87, O14015, O14218, O49691, O59835, O60153, P0C9Y6, P13200, P29832, P36103, P41884, P43587, P46583, P53222, Q09356, Q11091, Q196X1, Q1DR50, Q4R309, Q59ZU1, Q59ZW4, Q6BSZ8, Q6CNA0, Q6DDH0, Q6FUM5, Q6GLB0, Q6R7J4, Q750F0, Q88889

Diamond homologs: P10962, P46435, Q1RML7, Q55DJ3, Q66L33, Q6NYD4, Q6P7N1, Q7ZYG5, Q8BGS0, Q9BXY0, Q9UTE6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 121 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Peptide chain elongation	9	14.8×	4e-07
Viral mRNA Translation	9	14.8×	4e-07
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	9	14.7×	4e-07
rRNA modification in the nucleus and cytosol	6	14.6×	5e-05
Selenocysteine synthesis	9	14.1×	4e-07
Eukaryotic Translation Termination	9	14.1×	4e-07
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	9	13.8×	4e-07
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA	9	13.8×	4e-07

GO biological processes:

GO term	Partners	Fold	FDR
ribosomal large subunit biogenesis	6	23.8×	2e-05
cytoplasmic translation	10	16.5×	1e-07
ribosomal small subunit biogenesis	8	16.3×	6e-06
rRNA processing	12	15.2×	1e-08
regulation of alternative mRNA splicing, via spliceosome	6	13.1×	6e-04
regulation of RNA splicing	5	9.8×	9e-03
translation	10	9.2×	2e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

66 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	42
Likely benign	9
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
88868	NM_001102401.4(TTI2):c.1307T>A (p.Ile436Asn)	Pathogenic

SpliceAI

1198 predictions. Top by Δscore:

Variant	Effect	Δscore
8:33485222:G:GG	donor_gain	1.0000
8:33488372:TTGCA:T	acceptor_loss	1.0000
8:33488373:TGCA:T	acceptor_loss	1.0000
8:33488374:GCA:G	acceptor_loss	1.0000
8:33488375:CA:C	acceptor_loss	1.0000
8:33488376:AGGT:A	acceptor_loss	1.0000
8:33488377:GGTT:G	acceptor_gain	1.0000
8:33488428:G:GA	donor_loss	1.0000
8:33488513:A:AG	acceptor_gain	1.0000
8:33488514:T:G	acceptor_gain	1.0000
8:33488518:A:AG	acceptor_gain	1.0000
8:33488519:G:GT	acceptor_gain	1.0000
8:33488519:GA:G	acceptor_gain	1.0000
8:33488519:GAA:G	acceptor_gain	1.0000
8:33488519:GAAC:G	acceptor_gain	1.0000
8:33488519:GAACC:G	acceptor_gain	1.0000
8:33488625:GAAAG:G	donor_gain	1.0000
8:33488626:AAAGG:A	donor_loss	1.0000
8:33488627:AAGGT:A	donor_loss	1.0000
8:33488628:AG:A	donor_loss	1.0000
8:33488629:GGTA:G	donor_loss	1.0000
8:33488630:G:T	donor_loss	1.0000
8:33488631:T:A	donor_loss	1.0000
8:33488733:GGACA:G	acceptor_gain	1.0000
8:33489140:G:GG	donor_gain	1.0000
8:33495427:G:GT	donor_gain	1.0000
8:33495540:A:AC	acceptor_loss	1.0000
8:33495612:A:G	donor_gain	1.0000
8:33495617:G:GG	donor_gain	1.0000
8:33496614:AT:A	acceptor_gain	1.0000

AlphaMissense

1995 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:33488384:T:A	W8R	0.999
8:33488384:T:C	W8R	0.999
8:33488569:T:C	C39R	0.999
8:33488584:T:C	C44R	0.999
8:33488609:C:A	A52D	0.999
8:33488790:T:A	W78R	0.999
8:33488790:T:C	W78R	0.999
8:33488792:G:C	W78C	0.999
8:33488792:G:T	W78C	0.999
8:33489040:T:C	L98P	0.999
8:33489074:T:G	C109W	0.999
8:33489077:G:C	K110N	0.999
8:33489077:G:T	K110N	0.999
8:33489106:T:C	L120P	0.999
8:33489112:G:C	R122P	0.999
8:33489124:T:C	L126P	0.999
8:33495558:C:A	A155D	0.999
8:33495560:G:C	A156P	0.999
8:33495561:C:A	A156D	0.999
8:33495575:G:C	A161P	0.999
8:33495579:T:A	I162N	0.999
8:33495591:T:C	L166S	0.999
8:33495603:T:C	L170P	0.999
8:33488386:G:C	W8C	0.998
8:33488386:G:T	W8C	0.998
8:33488411:T:C	C17R	0.998
8:33488412:G:A	C17Y	0.998
8:33488539:T:C	C29R	0.998
8:33488540:G:A	C29Y	0.998
8:33488541:C:G	C29W	0.998

dbSNP variants (sampled 300 via entrez): RS1000107618 (8:33492491 A>G), RS1000497496 (8:33484529 T>A,C), RS1000609111 (8:33497389 C>T), RS1000774633 (8:33484737 C>A,T), RS1001079798 (8:33490710 T>C), RS1001490144 (8:33498739 A>C), RS1001543862 (8:33495695 T>A,G), RS1001696454 (8:33489384 T>C), RS1001704809 (8:33483452 G>C), RS1001940541 (8:33493815 C>T), RS1002127451 (8:33489609 A>C), RS1002340675 (8:33500461 T>C), RS1002544993 (8:33494330 C>T), RS1002867055 (8:33500754 A>C,G), RS1003265715 (8:33488080 C>T)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:615541

GenCC curated gene-disease

Mondo (2): severe intellectual disability-short stature-behavioral abnormalities-facial dysmorphism syndrome (MONDO:0014238), microcephaly (MONDO:0001149)

Orphanet (1): Severe intellectual disability-short stature-behavioral abnormalities-facial dysmorphism syndrome (Orphanet:391307)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000252	Microcephaly

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006626_14	Pulse pressure	1.000000e-09
GCST009391_574	Metabolite levels	7.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005763	pulse pressure measurement
EFO:0021604	hypoxanthine measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects methylation, decreases expression	2
sodium arsenite	affects cotreatment, increases abundance, increases expression, decreases expression	2
Resveratrol	affects cotreatment, decreases expression, increases expression	2
Estradiol	increases expression	2
FR900359	affects phosphorylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
tetrahydropalmatine	decreases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
1-nitropyrene	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluoro-n-nonanoic acid	increases expression	1
bisphenol S	affects expression	1
jinfukang	decreases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Leflunomide	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	increases expression, affects cotreatment, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Ethyl Methanesulfonate	decreases expression	1
Ivermectin	decreases expression	1
Lipopolysaccharides	affects cotreatment, decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Methyl Methanesulfonate	decreases expression	1
Plant Extracts	increases expression, affects cotreatment	1
Ribonucleotides	affects binding	1
Smoke	decreases expression	1
Dronabinol	decreases expression	1

Clinical trials (associated diseases)

17 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05518188	PHASE1/PHASE2	RECRUITING	Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
NCT00001639	Not specified	COMPLETED	Evaluation of Patients With Unresolved Chromosome Abnormalities
NCT01151462	Not specified	WITHDRAWN	Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.
NCT01565005	Not specified	COMPLETED	Microcephaly Genetic Deficiency in Neural Progenitors
NCT02510170	Not specified	COMPLETED	Fetal and Maternal Head Circumference During Pregnancy in Israeli Population
NCT02741882	Not specified	COMPLETED	Zika and Microcephaly: Case-control Study
NCT02943304	Not specified	COMPLETED	Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero
NCT03255369	Not specified	UNKNOWN	Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
NCT03325946	Not specified	RECRUITING	The FBRI VTC Neuromotor Research Clinic
NCT03330600	Not specified	COMPLETED	Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome
NCT03548779	Not specified	COMPLETED	North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
NCT03651687	Not specified	COMPLETED	Guangzhou Surveillance and Clinical Study in Microcephaly (GSCSM)
NCT03922594	Not specified	TERMINATED	Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia
NCT04816175	Not specified	COMPLETED	Intensive Therapy for Children With Microcephaly, Hyperkinetic Movements, or Global Developmental Delay
NCT05322980	Not specified	COMPLETED	Summary of Infants Weighing 500 Grams or Less
NCT06019182	Not specified	RECRUITING	MEHMO Natural History and Biomarkers
NCT06566066	Not specified	RECRUITING	Register for Patients With Thyroid Hormone Resistance.